Lantern Pharma debuts Zeta.ai platform
- Lantern Pharma said on April 24 that it will hold the first fully public live demo of withZeta.ai on April 30, after unveiling the oncology research platform at Nasdaq MarketSite and AACR 2026. - The company says withZeta.ai is commercially live now, with introductory, academic and commercial subscription tiers, and that the system draws on RADR, Lantern’s platform built on about 200 billion oncology data points. - The launch turns Lantern’s internal oncology software into a subscription product and public-facing pitch to investors and researchers. (lanternpharma.com)
Lantern Pharma is taking its cancer-drug software platform withZeta.ai from private demos to a public live demonstration on April 30, 2026. (financialcontent.com) The Dallas biotech launched withZeta.ai on April 14 and said the platform is already commercially live with introductory, academic and commercial subscription tiers. (lanternpharma.com) Lantern first showed the platform at Nasdaq MarketSite in New York on April 16, then at the American Association for Cancer Research annual meeting in San Diego from April 17 through April 22 at Booth 5054. (nasdaq.com) (lanternpharma.com) Drug discovery software like this is meant to search papers, genomic data, molecule data and clinical results faster than a human team can do by hand. Lantern says withZeta.ai combines those steps in one natural-language system for rare-cancer research. (lanternpharma.com) (financialcontent.com) Lantern says withZeta.ai is built from its internal RADR platform, which the company describes as using about 200 billion oncology-focused data points and more than 200 machine-learning algorithms. (lanternpharma.com) The company says the software can help with biomarker discovery, molecular design, indication selection and clinical trial planning, all aimed at shortening oncology development timelines and cutting cost. (lanternpharma.com 1) (lanternpharma.com 2) Chief executive Panna Sharma is scheduled to lead two identical public sessions on April 30, one at 8:30 a.m. Eastern and one at 4:30 p.m. Eastern, with live walkthroughs and open question-and-answer sessions. (financialcontent.com) Lantern is framing the launch as more than a product demo. In its April 14 announcement, the company called subscriptions a new non-dilutive revenue stream alongside its clinical-stage oncology pipeline. (lanternpharma.com) The immediate test is whether Lantern can turn a platform pitched as an “AI co-scientist” into paying usage beyond its own labs. April’s Nasdaq, AACR and April 30 public demo are the company’s first try at making that case in public. (lanternpharma.com) (financialcontent.com)
